Swiss pharmaceutical giant Roche has achieved positive results from the phase III evERA study combining its experimental treatments giredestrant and everolimus against a specific form of breast cancer. The combination of the two substances, administered orally, resulted in a "significant" increase in the survival time of patients without disease progression, compared with the current standard of treatment consisting of endocrine therapy and everolimus. +Get the most important news from Switzerland in your inbox In its press release on Monday, the Swiss multinational stated that it did not at this stage have mature data on the total survival rate of patients with locally advanced or metastatic oestrogen receptor-positive (ER+) and human epidermal growth factor receptor-negative breast cancer who had already undergone prior treatment. The adverse side effects observed were comparable to those of the two substances administered separately. Roche points out that it is running no fewer ...
